$1.05
-0.01 (-0.94%)
Open$1.06
Previous Close$1.06
Day High$1.15
Day Low$1.05
52W High$4.98
52W Low$0.78
Volume—
Avg Volume1.58M
Market Cap135.33M
P/E Ratio—
EPS$-0.73
SectorBiotechnology
Analyst Ratings
Buy
12 analysts
Price Target
+1,763.8% upside
Current
$1.05
$1.05
Target
$19.57
$19.57
$11.03
$19.57 avg
$23.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 80.98M | 111.07M | 66.42M |
| Net Income | -141,955,005 | -175,229,055 | 9.87M |
| Profit Margin | -175.3% | -166.5% | 14.9% |
| EBITDA | -120,226,681 | -156,652,512 | 12.50M |
| Free Cash Flow | — | — | 3.90M |
| Rev Growth | -27.1% | -27.1% | +3.3% |
| Debt/Equity | 3.72 | 3.72 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |